{"schema_version":"secwatch.filing_event.v1","accession":"0001999371-25-011053","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.975478+00:00","generated_at":"2026-05-17T15:21:28.366558+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Tonix Q2 net loss $28.3M; cash $125.3M; FDA PDUFA Aug 15 for TNX-102 SL","bullets":["Net product revenue $2.0M (down from $2.2M YoY); SG&A surged to $16.2M from $7.5M on pre-launch spend.","Cash $125.3M at June 30; plus $51.5M raised in Q3 2025; runway into Q3 2026.","FDA PDUFA date Aug 15, 2025 for TNX-102 SL (fibromyalgia); Fast Track designation.","First patient dosed in DoD-funded OASIS trial of TNX-102 SL for acute stress reaction.","Appointed Joseph Hand as General Counsel and James Hunter to board; added to Russell 2000/3000."],"urls":{"canonical":"https://secwatch.observer/filing/0001999371-25-011053","json":"https://secwatch.observer/filing/0001999371-25-011053.json","markdown":"https://secwatch.observer/filing/0001999371-25-011053.md","text":"https://secwatch.observer/filing/0001999371-25-011053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000199937125011053/0001999371-25-011053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000199937125011053/tnxp-8k_081125.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:21:28.366558+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}